Imagine if your dentist could see exactly which germs are attacking your dental implant instead of just guessing. This tool acts like a high-tech fingerprint scanner for bacteria in your mouth. It tells the doctor exactly what is causing the inflammation and which medicine will actually kill those specific germs.
Dentists currently lack reliable tools to detect early implant infections or predict their progression, forcing them to rely on general, empirical treatments that may fail.
A metagenomic-based diagnostic tool and AI-driven Decision Support System (DSS) featuring robotic sample processing and antibiotic resistance identification.
If you are a clinic owner dealing with high rates of implant failure and patient dissatisfaction — this project developed a precision-medicine tool that predicts disease progression and provides personalized treatment recommendations.
If you are a lab provider dealing with slow turnaround times for microbiome tests — this project developed a robotic automation process that reduces sample processing time from 10 to 2 working days.
If you are a pharma company dealing with the rise of antibiotic resistance in oral health — this project developed an antibiotic resistance gene identification feature to support informed therapeutic choices.
The project implemented robotic automation and optimized laboratory procedures, resulting in a 32% reduction in consumables and an 80% reduction in personnel cost per sample.
Yes, the project has already transitioned from manual to robotic sample processing, reducing the turnaround time from 10 working days to 2 working days.
The project includes the definition of an IPR management plan to protect the knowledge generated and a robust business plan for product exploitation.
It introduces an antibiotic resistance gene identification feature, allowing dentists to move away from empirical therapies toward informed therapeutic choices.
The project is active from May 1, 2023, to April 30, 2026.
The project is led by a single Italian SME, PreBiomics SRL, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the company is directly managing the transition from 10 years of research into a market-ready product without the overhead of academic partners in this specific phase.
Contact PreBiomics SRL in Italy for licensing and partnership inquiries.
Contact us to explore integration of PreBiomicsPMT into your dental diagnostic workflow.
